Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997
|
| 12/21/2004 |
  |
Rigel Initiates Clinical Trial in Rheumatoid Arthritis |
|
| 12/1/2004 |
|
Rigel to Host Investor Briefing on December 1, 2004 |
|
| 11/22/2004 |
|
Poor Bioavailability Results in Insignificant Clinical Effects for Rigel R803 in Phase I/II HCV Trial |
|
| 11/15/2004 |
|
Merck and Rigel Pharmaceuticals Sign Ligase Partnership With a Primary Focus on Cancer |
|
| 11/12/2004 |
|
Rigel to Present at the CSFB Annual Healthcare Conference on November 17, 2004 |
|
| 11/5/2004 |
|
Rigel Announces Third Quarter 2004 Financial Results |
|
| 10/22/2004 |
|
Rigel to Present at the Rodman & Renshaw Techvest Healthcare Conference on October 26, 2004 |
|
| 10/20/2004 |
|
Rigel Presents Preclinical Data at the 68th Annual Scientific Meeting of the American College of Rheumatology |
|
| 9/21/2004 |
|
Rigel to Present at the UBS Global Life Sciences Conference on September 27, 2004 |
|
| 9/2/2004 |
|
Rigel to Present at the Thomas Weisel Partners Healthcare Tailwinds Conference on September 8, 2004 |
|
| 8/3/2004 |
|
Rigel Announces Second Quarter 2004 Financial Results |
|
| 8/2/2004 |
|
Rigel's R112 Demonstrates Robust Effect in Reducing Symptoms of Allergic Rhinitis in Large Phase II Clinical Trial |
|
| 7/28/2004 |
|
Rigel to Present at the Adams Harkness 2004 Summer Seminar on August 4, 2004 |
|
| 7/22/2004 |
|
Rigel Reports Significant Progress in Aurora Kinase Program for the Treatment of Cancer |
|
| 6/16/2004 |
|
Rigel Appoints Raul Rodriguez as Executive Vice President and Chief Operating Officer |
|
| 6/10/2004 |
|
Rigel to Present at Two Investor Conferences |
|
| 6/9/2004 |
|
Rigel Granted Key Patents in Ubiquitin Ligase Field |
|
| 6/4/2004 |
|
Rigel to Present at the BIO 2004 International Convention June 7, 2004 |
|
| 5/24/2004 |
|
Rigel Initiates Phase I/II Trial of R803 for the Treatment of Hepatitis C Virus |
|
| 5/20/2004 |
|
Rigel to Present at the UBS 2004 Global Specialty Pharmaceuticals Conference on May 24, 2004 |
|
| 5/6/2004 |
|
Rigel to Present at the Rodman & Renshaw Techvest Global Healthcare Conference on May 13, 2004 |
|
| 5/4/2004 |
|
Rigel Announces First Quarter 2004 Financial Results |
|
| 4/29/2004 |
|
Rigel to Present at the 4th Annual Fortis Bank Biotech Conference |
|
| 4/20/2004 |
|
Rigel Initiates Phase II Clinical Trial of R112 for Allergic Rhinitis |
|
| 4/15/2004 |
|
Rigel to Present at the 2nd Annual White Mountain Capital Biotechnology Conference |
|
| 3/25/2004 |
|
Rigel Announces Underwriters' Exercise of Option to Purchase Additional Shares |
|
| 3/18/2004 |
|
Rigel Presents Positive Results of R112 Clinical Trial for Treatment of Allergic Rhinitis |
|
| 2/24/2004 |
|
Rigel to Present at the 6th Annual BIO CEO and Investor Conference |
|
| 2/20/2004 |
|
Rigel Announces Pricing of Common Stock Offering |
|
| 2/6/2004 |
|
Rigel Announces Offering of 3,165,000 Shares of Common Stock |
|
| 2/3/2004 |
|
Rigel Announces Fourth Quarter and Year End 2003 Financial Results |
|
| 1/28/2004 |
|
Rigel Selects R406 as Lead Drug Candidate for Rheumatoid Arthritis |
|
| 1/26/2004 |
|
Rigel's R803 for HCV Achieves Favorable Safety Profile |
|
| 1/21/2004 |
|
Rigel Pharmaceuticals Appoints Hollings C. Renton to Board of Directors |
|
| 1/6/2004 |
|
Rigel Announces Issuance of HCV and Inflammation Patents |
|
rigel in the news
